Pulsatile Drug Dosing Beats Sustained Activation for Liver Disease Treatment

For decades, pharmacological dogma has favored sustained drug exposure: keep receptors activated as long as possible to maximize therapeutic effect. A new commentary published in Cell Metabolism challenges this assumption in the context of liver disease, with potentially broad implications for metabolic therapeutics.

The farnesoid X receptor (FXR) is a nuclear receptor activated by bile acids that plays a central role in regulating bile acid synthesis, lipid metabolism, glucose homeostasis, and liver inflammation. It has become a major drug target for conditions such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis, and other metabolic liver diseases. However, sustained FXR agonism has been associated with off-target transcriptional effects and receptor desensitization over time.

Sun, Feng, and Li highlight the work of Zang and colleagues, who studied linafexor, a rapidly cleared FXR agonist. Because linafexor is metabolized quickly, it produces pulsatile rather than continuous receptor activation. This rhythmic on-off pattern was found to preserve receptor responsiveness, preventing the receptor from becoming desensitized or downregulated. It also reduced broad transcriptional disruption — a common side effect of sustained nuclear receptor activation — while maintaining or improving therapeutic efficacy and safety in liver disease models.

The key implication is that temporal alignment — designing drugs to activate receptors in bursts that mirror natural biological rhythms — may be a superior strategy to prolonged activation. This is especially relevant for nuclear receptors like FXR, which interact with thousands of genomic targets and can cause widespread transcriptional dysregulation when persistently stimulated.

For clinicians and researchers in metabolic health and longevity, this reframes how pharmacokinetic properties should be evaluated. A drug's speed of clearance should be considered a feature, not a flaw, if it enables pulsatile receptor engagement. The findings may influence the design of next-generation metabolic and liver therapeutics.